Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GARFIELD-VTE investigators
Vis graf over relationer

Venous thromboembolism (VTE) is common in cancer patients and is an important cause of morbidity and mortality. The Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE (ClinicalTrials.gov: NCT02155491) is a prospective, observational study of 10,684 patients with objectively diagnosed VTE from 415 sites in 28 countries. We compared baseline characteristics, VTE treatment patterns, and 1-year outcomes (mortality, recurrent VTE and major bleeding) in 1075 patients with active cancer, 674 patients with a history of cancer, and 8935 patients without cancer. Patients with active cancer and history of cancer were older than cancer-free patients, with median ages of 64.8, 68.9, and 58.4 years, respectively. The most common sites of active cancer were lung (14.5%), colorectal (11.0%), breast (10.6%), and gynaecological (10.3%). Active cancer patients had a higher incidence of upper limb and vena cava thrombosis than cancer-free patients (9.0% vs 4.8% and 5.1% vs 1.4%, respectively), and were more likely to receive parenteral anticoagulation as monotherapy than cancer-free patients (57.8% vs 12.1%), and less likely to receive DOACs (14.2% vs 50.6%). Rates of death, recurrent VTE, and major bleeding were higher in active cancer patients than in cancer-free patients, with hazard ratios (95% confidence intervals) of 14.2 (12.1-16.6), 1.6 (1.2-2.0) and 3.8 (2.9-5.0), respectively. VTE was the second most common cause of death in patients with active cancer or history of cancer. In patients with VTE, those with active cancer are at higher risk of death, recurrence, and major bleeding than those without cancer.

OriginalsprogEngelsk
TidsskriftJournal of Thrombosis and Thrombolysis
Vol/bind50
Udgave nummer2
Sider (fra-til)267-277
Antal sider11
ISSN0929-5305
DOI
StatusUdgivet - aug. 2020

ID: 61669038